Search by Drug Name or NDC
NDC 10135-0737-60 Selegiline Hydrochloride 5 mg/1 Details
Selegiline Hydrochloride 5 mg/1
Selegiline Hydrochloride is a ORAL CAPSULE in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Marlex Pharmaceuticals, Inc.. The primary component is SELEGILINE HYDROCHLORIDE.
MedlinePlus Drug Summary
Selegiline is used to help control the symptoms of Parkinson's disease (PD; a disorder of the nervous system that causes difficulties with movement, muscle control, and balance) in people who are taking levodopa and carbidopa combination (Sinemet). Selegiline may help people with Parkinson's disease by decreasing the dose of levodopa/carbidopa needed to control symptoms, stopping the effects of levodopa/carbidopa from wearing off between doses, and increasing the length of time that levodopa/carbidopa will continue to control symptoms. Selegiline is in a group of medications called monoamine oxidase type B (MAO-B) inhibitors. It works by increasing the amount of dopamine (a natural substance that is needed to control movement) in the brain.
Related Packages: 10135-0737-60Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Selegiline
Product Information
| NDC | 10135-0737 |
|---|---|
| Product ID | 10135-737_f602e53a-57fd-20e1-e053-2a95a90a7812 |
| Associated GPIs | 73300030100120 |
| GCN Sequence Number | 026516 |
| GCN Sequence Number Description | selegiline HCl CAPSULE 5 MG ORAL |
| HIC3 | H6A |
| HIC3 Description | ANTIPARKINSONISM DRUGS,OTHER |
| GCN | 15603 |
| HICL Sequence Number | 016483 |
| HICL Sequence Number Description | SELEGILINE HCL |
| Brand/Generic | Generic |
| Proprietary Name | Selegiline Hydrochloride |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Selegiline Hydrochloride |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | CAPSULE |
| Route | ORAL |
| Active Ingredient Strength | 5 |
| Active Ingredient Units | mg/1 |
| Substance Name | SELEGILINE HYDROCHLORIDE |
| Labeler Name | Marlex Pharmaceuticals, Inc. |
| Pharmaceutical Class | Monoamine Oxidase Inhibitor [EPC], Monoamine Oxidase Inhibitors [MoA], Monoamine Oxidase Type B Inhibitor [EPC], Monoamine Oxidase-B Inhibitors [MoA] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA075352 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 10135-0737-60 (10135073760)
| NDC Package Code | 10135-737-60 |
|---|---|
| Billing NDC | 10135073760 |
| Package | 60 CAPSULE in 1 BOTTLE (10135-737-60) |
| Marketing Start Date | 2021-05-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |